1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Plevin, M.J. Zhang, J. Guo, C. Roeder, R.G. Ikura, M. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 103 10242 10247 10.1073/pnas.0603463103 16803958 The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain 2006 10.2210/pdb2h7b/pdb pdb_00002h7b 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 11887.721 Core-binding factor, ML1-ETO residues 83-185, C169A 1 man polymer runt domain, alpha subunit 2, translocated to 1, cyclin D-related no no GSARQLSKLKRFLTTLQQFGNDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELL HAARLAKQNPAQYLAQHEQLLLDAS GSARQLSKLKRFLTTLQQFGNDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELL HAARLAKQNPAQYLAQHEQLLLDAS A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia sample ETO 9606 Homo sapiens 562 Escherichia coli BL21(DE3) Rosetta plasmid pGEX-4T-1 database_2 pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2006-07-11 1 1 2008-05-01 1 2 2011-07-13 1 3 2021-10-20 _database_2.pdbx_DOI _database_2.pdbx_database_accession _struct_ref_seq_dif.details RCSB Y RCSB 2006-06-01 REL REL This entry is the solution conformation of eTAFH bound to 17 residue AD1 peptide from human HEB. Structure of the bound AD1 peptide was not determined due to chemical exchange broadening of resonances from this molecule target function 100 20 NOESY 4D_13C/15N-separated_NOESY 70 mM 6 AMBIENT 25 K torsion angle dynamics 1 lowest energy 0.7 mM eTAFH U-15N, 13C, 20 mM sodium phosphate, pH 6.0, 50 mM NaCl, 1mM PMSF, 1mM AEBSF, 0.25 mM sodium azide, 90% H2O, 10% D2O 90% H2O/10% D2O GUNTERT, P. ET AL. refinement CYANA GUNTERT, P. ET AL. structure solution CYANA 500 Varian UNITYPLUS 600 Varian UNITYPLUS 800 Varian UNITYPLUS GLY -1 n 1 GLY -1 A SER 0 n 2 SER 0 A ALA 1 n 3 ALA 1 A ARG 2 n 4 ARG 2 A GLN 3 n 5 GLN 3 A LEU 4 n 6 LEU 4 A SER 5 n 7 SER 5 A LYS 6 n 8 LYS 6 A LEU 7 n 9 LEU 7 A LYS 8 n 10 LYS 8 A ARG 9 n 11 ARG 9 A PHE 10 n 12 PHE 10 A LEU 11 n 13 LEU 11 A THR 12 n 14 THR 12 A THR 13 n 15 THR 13 A LEU 14 n 16 LEU 14 A GLN 15 n 17 GLN 15 A GLN 16 n 18 GLN 16 A PHE 17 n 19 PHE 17 A GLY 18 n 20 GLY 18 A ASN 19 n 21 ASN 19 A ASP 20 n 22 ASP 20 A ILE 21 n 23 ILE 21 A SER 22 n 24 SER 22 A PRO 23 n 25 PRO 23 A GLU 24 n 26 GLU 24 A ILE 25 n 27 ILE 25 A GLY 26 n 28 GLY 26 A GLU 27 n 29 GLU 27 A ARG 28 n 30 ARG 28 A VAL 29 n 31 VAL 29 A ARG 30 n 32 ARG 30 A THR 31 n 33 THR 31 A LEU 32 n 34 LEU 32 A VAL 33 n 35 VAL 33 A LEU 34 n 36 LEU 34 A GLY 35 n 37 GLY 35 A LEU 36 n 38 LEU 36 A VAL 37 n 39 VAL 37 A ASN 38 n 40 ASN 38 A SER 39 n 41 SER 39 A THR 40 n 42 THR 40 A LEU 41 n 43 LEU 41 A THR 42 n 44 THR 42 A ILE 43 n 45 ILE 43 A GLU 44 n 46 GLU 44 A GLU 45 n 47 GLU 45 A PHE 46 n 48 PHE 46 A HIS 47 n 49 HIS 47 A SER 48 n 50 SER 48 A LYS 49 n 51 LYS 49 A LEU 50 n 52 LEU 50 A GLN 51 n 53 GLN 51 A GLU 52 n 54 GLU 52 A ALA 53 n 55 ALA 53 A THR 54 n 56 THR 54 A ASN 55 n 57 ASN 55 A PHE 56 n 58 PHE 56 A PRO 57 n 59 PRO 57 A LEU 58 n 60 LEU 58 A ARG 59 n 61 ARG 59 A PRO 60 n 62 PRO 60 A PHE 61 n 63 PHE 61 A VAL 62 n 64 VAL 62 A ILE 63 n 65 ILE 63 A PRO 64 n 66 PRO 64 A PHE 65 n 67 PHE 65 A LEU 66 n 68 LEU 66 A LYS 67 n 69 LYS 67 A ALA 68 n 70 ALA 68 A ASN 69 n 71 ASN 69 A LEU 70 n 72 LEU 70 A PRO 71 n 73 PRO 71 A LEU 72 n 74 LEU 72 A LEU 73 n 75 LEU 73 A GLN 74 n 76 GLN 74 A ARG 75 n 77 ARG 75 A GLU 76 n 78 GLU 76 A LEU 77 n 79 LEU 77 A LEU 78 n 80 LEU 78 A HIS 79 n 81 HIS 79 A ALA 80 n 82 ALA 80 A ALA 81 n 83 ALA 81 A ARG 82 n 84 ARG 82 A LEU 83 n 85 LEU 83 A ALA 84 n 86 ALA 84 A LYS 85 n 87 LYS 85 A GLN 86 n 88 GLN 86 A ASN 87 n 89 ASN 87 A PRO 88 n 90 PRO 88 A ALA 89 n 91 ALA 89 A GLN 90 n 92 GLN 90 A TYR 91 n 93 TYR 91 A LEU 92 n 94 LEU 92 A ALA 93 n 95 ALA 93 A GLN 94 n 96 GLN 94 A HIS 95 n 97 HIS 95 A GLU 96 n 98 GLU 96 A GLN 97 n 99 GLN 97 A LEU 98 n 100 LEU 98 A LEU 99 n 101 LEU 99 A LEU 100 n 102 LEU 100 A ASP 101 n 103 ASP 101 A ALA 102 n 104 ALA 102 A SER 103 n 105 SER 103 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A ALA 1 -93.37 -67.27 1 A SER 22 173.08 163.52 1 A GLU 24 -51.48 -75.80 1 A VAL 33 -49.14 -73.18 1 A SER 48 -75.50 -72.24 1 A ASN 55 -57.81 -176.72 1 A PHE 56 59.95 167.40 1 A PHE 61 63.54 78.53 1 A PHE 65 -70.35 -73.05 1 A LEU 98 -90.88 50.62 1 A LEU 99 -113.87 -74.60 2 A ALA 1 -94.60 -72.95 2 A VAL 33 -50.09 -71.26 2 A LEU 58 179.92 126.79 2 A PHE 61 57.08 80.29 2 A ARG 82 -51.84 -70.61 2 A LEU 100 -51.84 -71.04 3 A SER 0 -117.44 54.38 3 A ALA 1 -93.21 -60.98 3 A VAL 33 -49.66 -71.82 3 A SER 48 -73.57 -72.27 3 A VAL 62 -97.19 -63.55 3 A PHE 65 -66.13 -70.30 3 A LEU 98 -92.07 53.90 3 A ASP 101 -64.65 94.05 4 A VAL 33 -50.47 -73.95 4 A THR 54 -48.29 -75.24 4 A ASN 55 -154.07 -62.75 4 A PHE 56 179.82 -59.84 4 A PHE 61 65.48 78.00 4 A LEU 99 -56.17 100.86 4 A ASP 101 -68.72 86.37 5 A SER 0 -179.36 -166.42 5 A ALA 1 -67.41 -72.21 5 A SER 22 176.87 163.15 5 A GLU 24 -53.72 -72.67 5 A VAL 33 -50.61 -71.48 5 A PRO 57 -69.75 -177.57 5 A LEU 58 -59.01 108.30 5 A VAL 62 -95.58 -60.29 5 A LEU 98 -109.59 53.65 5 A ASP 101 -65.09 97.95 5 A ALA 102 -109.91 -62.97 6 A SER 0 -113.08 55.96 6 A ALA 1 -93.45 -61.03 6 A SER 22 178.96 160.24 6 A GLU 24 -53.45 -76.73 6 A VAL 33 -51.25 -72.53 6 A PHE 65 -61.02 -72.64 6 A ASP 101 -65.42 91.59 7 A SER 22 179.58 161.06 7 A GLU 24 -52.78 -77.13 7 A VAL 33 -48.80 -70.83 7 A THR 54 -55.43 -177.80 7 A ASN 55 -39.47 -70.11 7 A PHE 56 179.41 -59.59 7 A PHE 61 64.34 77.69 7 A VAL 62 -95.27 -61.30 7 A ALA 102 -61.09 -75.00 8 A VAL 33 -49.96 -71.42 8 A THR 54 -71.12 -75.09 8 A PRO 57 -69.75 99.39 8 A LEU 98 -101.56 77.04 8 A LEU 100 -98.08 -66.69 9 A SER 22 178.85 160.18 9 A GLU 24 -53.53 -77.94 9 A VAL 33 -49.95 -72.30 9 A ASN 55 -54.37 176.48 9 A PHE 61 52.10 80.25 9 A GLU 96 -90.20 -64.06 9 A LEU 98 -94.87 41.72 9 A LEU 100 -138.24 -60.01 10 A SER 0 -119.67 62.13 10 A ALA 1 -93.35 -61.19 10 A SER 22 178.09 160.61 10 A VAL 33 -49.42 -71.87 10 A SER 48 -69.75 -72.50 10 A ASN 55 -60.54 -168.32 10 A PHE 56 57.06 169.72 10 A LEU 58 -38.24 136.82 10 A PRO 60 -69.71 -87.60 10 A LEU 99 -65.94 -170.78 10 A LEU 100 -68.41 86.16 10 A ASP 101 -96.58 30.24 10 A ALA 102 -54.33 -70.07 11 A ALA 1 -94.38 -72.20 11 A SER 22 174.73 162.32 11 A VAL 33 -49.66 -70.35 11 A LEU 58 -45.98 106.50 11 A VAL 62 -98.28 -61.53 11 A ASP 101 -63.74 93.43 12 A SER 0 -117.16 53.31 12 A GLU 24 -52.83 -70.60 12 A VAL 33 -49.58 -71.19 12 A ASN 55 -53.53 176.49 12 A PHE 56 61.46 163.71 12 A LEU 58 -177.67 133.66 12 A PHE 61 -103.99 79.46 12 A VAL 62 -99.32 -67.48 12 A LEU 99 -60.91 -168.82 12 A ALA 102 -58.57 178.23 13 A ALA 1 -93.90 -65.54 13 A SER 22 178.98 159.45 13 A GLU 24 -53.13 -77.02 13 A VAL 33 -50.90 -73.59 13 A PHE 56 63.30 162.03 13 A PRO 57 -69.78 -168.39 13 A PHE 65 -66.26 -73.43 13 A LEU 99 -109.21 76.11 14 A SER 0 -97.82 31.50 14 A ALA 1 -90.71 -67.79 14 A SER 22 179.14 159.97 14 A GLU 24 -53.53 -77.57 14 A THR 54 -51.19 170.54 14 A PHE 56 179.78 -60.01 14 A PRO 57 -69.74 85.95 14 A PRO 60 -69.74 -86.74 14 A LEU 99 -59.66 -175.02 14 A LEU 100 -65.83 88.20 15 A SER 0 -111.55 51.75 15 A SER 22 178.76 161.70 15 A VAL 33 -49.91 -73.11 15 A ASN 55 -60.80 -177.20 15 A PHE 56 60.68 163.86 15 A PHE 61 50.67 81.70 15 A VAL 62 -97.09 -62.29 15 A PHE 65 -66.99 -71.30 15 A LEU 98 -107.05 54.41 15 A LEU 99 -56.75 -175.54 16 A SER 0 -101.48 60.71 16 A ALA 1 -93.63 -63.77 16 A SER 22 178.06 160.63 16 A VAL 33 -49.47 -71.58 16 A THR 54 -68.58 -83.08 16 A ASN 55 172.67 161.07 16 A PHE 56 60.72 167.64 16 A LEU 58 -29.70 133.57 17 A SER 0 -179.39 -166.21 17 A ALA 1 -67.18 -70.31 17 A SER 22 178.59 161.15 17 A VAL 33 -49.98 -71.42 17 A PHE 56 63.78 168.36 17 A LYS 85 31.01 49.55 17 A LEU 99 -69.50 -73.57 18 A SER 0 -111.05 64.25 18 A ALA 1 -93.87 -64.38 18 A SER 22 169.36 156.98 18 A GLU 24 -53.39 -70.38 18 A SER 48 -58.60 -72.29 18 A ASN 55 -54.86 177.64 18 A PHE 56 60.68 163.82 18 A PHE 61 61.36 77.82 18 A VAL 62 -95.99 -61.13 19 A SER 0 -107.85 71.78 19 A ALA 1 -94.37 -71.80 19 A GLU 24 -54.49 -75.83 19 A VAL 33 -50.90 -71.45 19 A ASP 101 -93.51 47.62 20 A ALA 1 -91.39 -63.56 20 A SER 22 175.19 161.53 20 A VAL 33 -50.35 -72.43 20 A ASN 55 -56.56 -178.55 20 A PHE 56 61.16 162.98 20 A LEU 58 -175.04 131.67 20 A PHE 61 58.48 78.34 20 A VAL 62 -95.76 -65.22 20 A LEU 100 -130.99 -52.49 Solution structure of the eTAFH domain from the human leukemia-associated fusion protein AML1-ETO 1 N N A ALA 1 A ALA 3 HELX_P A LEU 4 A LEU 6 5 1 4 A SER 5 A SER 7 HELX_P A PHE 17 A PHE 19 1 2 13 A PHE 17 A PHE 19 HELX_P A SER 22 A SER 24 1 3 6 A SER 22 A SER 24 HELX_P A ASN 38 A ASN 40 1 4 17 A THR 42 A THR 44 HELX_P A THR 54 A THR 56 1 5 13 A VAL 62 A VAL 64 HELX_P A ALA 68 A ALA 70 1 6 7 A ASN 69 A ASN 71 HELX_P A ALA 81 A ALA 83 1 7 13 A ARG 82 A ARG 84 HELX_P A ALA 84 A ALA 86 5 8 3 A ALA 89 A ALA 91 HELX_P A GLN 94 A GLN 96 1 9 6 TRANSCRIPTION 4 HELIX BUNDLE, TRANSCRIPTION Q7Z4J5_HUMAN UNP 1 83 Q7Z4J5 ARQLSKLKRFLTTLQQFGNDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELLHC ARLAKQNPAQYLAQHEQLLLDAS 83 185 2H7B 1 103 Q7Z4J5 A 1 3 105 1 cloning artifact GLY -1 2H7B A Q7Z4J5 UNP 1 1 cloning artifact SER 0 2H7B A Q7Z4J5 UNP 2 1 CYS engineered mutation ALA 80 2H7B A Q7Z4J5 UNP 162 82 1 P 1